CoChat

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Open access
Leipold, Alexander M., Werner, Rudolf A., Düll, Johannes, Jung, Pius, John, Mara, Stanojkovska, Emilia, Zhou, Xiang, Hornburger, Hannah, Ruckdeschel, Anna, Dietrich, Oliver, Imdahl, Fabian, Krammer, Tobias, Knop, Stefan, Rosenwald, Andreas, Buck, Andreas, Sander, Leif Erik, Einsele, Hermann, Kortüm, K. Martin, Saliba, Antoine-Emmanuel, Rasche, Leo · 2023 · Leukemia
Cited by 36

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel), a BCMA targeting CAR T-cell therapy, and used single-cell RNA-seq (scRNA-seq) to identify a Th17.1 driven autoimmune mechanism as the biological underpinning of this phenomenon. By integrating datasets of various lung pathological conditions, we revealed transcriptomic similarities between post CAR T pulmonary lesions and sarcoidosis. Furthermore, we explored a noninvasive PET based diagnostic approach and showed that tracers binding to CXCR4 complement FDG PET imaging in this setting, allowing discrimination between immune-mediated changes and true relapse after CAR T-cell treatment. In conclusion, our study highlights a Th17.1 driven autoimmune phenomenon after CAR T, which may be misinterpreted as disease relapse, and that imaging with multiple PET tracers and scRNA-seq could help in this diagnostic dilemma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-023-01824-0

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 36

Metadata

Authors
Leipold, A. M., Werner, R. A., Düll, J., Jung, P., John, M., Stanojkovska, E., Zhou, X., Hornburger, H., Ruckdeschel, A., Dietrich, O., Imdahl, F., Krammer, T., Knop, S., Rosenwald, A., Buck, A., Sander, L. E., Einsele, H., Kortüm, K. M., Saliba, A.-E., & Rasche, L.
Venue
Leukemia
Published
2023-01-31
Volume
37
Issue
3
Pages
650-658
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W4318619395
Cited by
36
References
14
FWCI
3.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. https://app.cochat.ai/papers/10.1038/s41375-023-01824-0
The paper
Leipold, A. M., Werner, R. A., Düll, J., Jung, P., John, M., Stanojkovska, E., Zhou, X., Hornburger, H., Ruckdeschel, A., Dietrich, O., Imdahl, F., Krammer, T., Knop, S., Rosenwald, A., Buck, A., Sander, L. E., Einsele, H., Kortüm, K. M., Saliba, A.-E., & Rasche, L. (2023). Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-023-01824-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.